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Abstract The most common non-surgical approaches for the
treatment of localized hepatocellular carcinoma remain hepatic
artery-delivered particles laden with chemotherapy (TACE), or
radioactivemicroparticles (TARE). External beam radiotherapy
has been an effective option in many parts of the world for
selected HCC patients, but now has an expanded role with
stereotactic and proton beam technologies. This review focuses
on existing evidence and current guidance for utilizing these
modalities for localized, but unresectable, non-transplantable
HCC patients.x
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Introduction
The incidence and mortality of hepatocellular carcinoma
(HCC) continues to increase worldwide and is the third lead-
ing cause of global cancer deaths [1]. In the USA, HCC
mortality has been rising steadily for more than two decades
with no plateau seen [2]. A dismal overall 5-year survival rate
of only 5 % is achieved, and more than 70 % of patients
present with advanced disease that cannot be approached with
curative intent—i.e., transplantation, resection, or tumors
<3 cm that can be ablated [3].
The focus of this review is limited to treatment of the
largest group of HCC patients seen worldwide—the approx-
imately 70 % who do not have curative options due to tumor
size, number and/or location, and do not have metastatic
disease. The most commonly employed approaches for con-
trol of HCC for the majority of patients therefore fall into two
categories, which will be presented in depth: hepatic artery
delivered therapies, and externally delivered radiation therapy.
Intra-Arterial Therapies
When related to the treatment of unresectable HCC, intra-
arterial therapies are a group of treatments where therapeutic
and/or embolic agents are intra-arterially directed to target
tumors. The unique double irrigation of the liver (through the
portal vein and the hepatic artery) and the predominantly
arterial irrigation of liver tumors, particularly primary liver
cancer, are the basis for intra-arterial therapies. The most com-
monly used techniques are transarterial chemoembolization
(TACE) with or without drug-eluting beads (DEB) and
transarterial radioembolization (TARE), also called selective
internal radiation therapy. TACE combines local drug delivery
with concurrent tumor-feeding artery embolization. TARE is a
form of brachytherapy in which intra-arterially injected
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microspheres loaded with yttrium 90 (90Y) serve as sealed
sources for internal radiation purposes.
Transarterial Chemoembolization
TACE embraces different procedures that share two different
aims: (1) to increase the exposure of tumor cells to cytotoxic
agents, and (2) to induce ischemic necrosis. This is usually
accomplished by the sequential intra-arterial injection of che-
motherapeutic agents and embolizing particles. The wide
variety of drug vehicles, cytotoxic agents, and embolizing
particles has introduced numerous variations worldwide and
no standard protocol has been uniformly adopted. Centers
have different choices regarding type and/or dose of the anti-
cancer agents used, use of lipiodol as a vehicle, embolizing
material, selectivity of catheter positioning, embolization
end-points, and schedule and/or interval of retreatment.
Although conventional TACE with administration of an
anticancer-in-lipiodol emulsion followed by embolic agents
has been the most popular technique, bland embolization is
still preferred in some centers, and TACE with drug eluting
particles (DEB-TACE) have replaced conventional regimens
in others.
Conventional Tace
In TACE of HCC, single-agent doxorubicin is most common-
ly used in Europe and Japan, while the combination of mito-
mycin C, doxorubicin, and cisplatin is more popular in the
United States. Single or combination agents are typically
emulsified in lipiodol, an oily contrast agent believed to
increase intratumoral retention of the cytotoxic agent. The
iodized oil persists selectively in the tumor for a few weeks
or months because of hemodynamic differences between
hypervascular hepatic tumors and liver parenchyma, and pre-
sumably because of the absence of Kupffer cells in tumors.
This is followed by embolization of the target vessels with
agents such as gelfoam (heterogeneous in size), or the more
recently calibrated polyvinyl alcohol, or acrylic copolymer
gelatin particles. The use of calibrated particles is increasing
worldwide since they can be chosen by size according to the
target vessel [4]. Vessel occlusion following injection of this
mixture results in lower peak plasma concentrations and in-
creased drug retention inside tumors. However, the therapeu-
tic benefit obtained from adding a cytotoxic agent or lipiodol
to bland embolization was challenged by the results of two
clinical trials conducted in the 1990s [5, 6] and two meta-
analyses [7, 8] suggesting that the antitumor effect is mainly
driven by ischemia.
The evidences that support the use of TACE for palliative
treatment of unresectable HCC are randomized controlled
trials [9, 10] in selected patients with preserved liver function.
In the Spanish trial [9], patients with preserved liver function
and free frommain portal vein thrombosis (PVT) were treated
with fixed interval chemoembolization or embolization, or
best supportive care. The 2-year survival rate after TACE
was 63 % compared to 27 % in the untreated patients
(P=0.009). In the Hong-Kong trial [10], patients with lobar or
branch PVT were included provided their liver function was
preserved, and 2-year survival rate of 31 %was again superior
to the 11 % observed in the control group (P=0.002). Three
other clinical trials had failed to show a superiority of TACE
compared to best supportive care or inactive treatments (such
as tamoxifen) in terms of survival [11–13]. Three meta-
analyses [7, 8, 14] have subsequently confirmed that TACE
improves survival of patients, and TACE has been established
as the standard of care for patients in the intermediate stage of
the Barcelona Clinic Liver Cancer (BCLC) staging system,
i.e., those with multinodular HCC, relatively preserved
liver function, absence of cancer-related symptoms, and no
evidence of vascular invasion or extrahepatic spread [15].
However, it should be noted that approximately one-half of
patients recruited in the two positive trials had one or two
tumor nodules and were likely early-stage patients in which
ablation was deemed unfeasible. In fact, the range of patients
treated by TACE in clinical practice has exceeded, by much
greater margins, intermediate-stage disease. As a result, re-
ported survivals are rather heterogeneous, ranging from 53 to
90 % at 1 year, 11 to 67 % at 2 years and 8 to 26 % at 5 years
[16–24]. Median survival averages 16 months, even in con-
temporary series with unrestricted patient selection [25–27].
By stage, reported median survival ranges from 16 to 45
months in the early BCLC A stage, from 15.6 to 18.2 months
in intermediate BCLC B stage, and from 6.8 to 13.6 in the
advanced BCLC C stage. Prognosis after TACE largely de-
pends on liver function [20, 22, 23, 28–30], tumor burden [16,
22, 23, 31] presence of portal vein invasion [10, 16, 17], and
most importantly, response to treatment [9, 32]. TACE is
generally contraindicated in patients with PVT, since occlu-
sion of arterial blood flow may induce liver failure. However,
superselective TACE may be safe in selected patients with
segmental branch invasion [33, 34].
TACE is generally a safe procedure, although it is frequent-
ly followed by side effects that can occasionally be severe.
The most common is post-embolization syndrome, consisting
of nausea, abdominal pain, and fever, which occurs in more
than 40 % of patients, but tends to be mild and transient. A
variable proportion of patients (20–45 %) show a transient
decline in liver function after TACE and acute liver decom-
pensation (appearance of ascites, encephalopathy or jaundice),
reported in 0.1–3 % of cases [35, 36]. Biliary and gastrointes-
tinal tract complications have been reported in 2–10 % [37,
38] and 1–5 % [34] of patients, respectively. Mortality rates
range widely, from 0.003 to 10 % in the different series [7, 16,
39], again reflecting differences in the target population and
373, Page 2 of 8 Curr Oncol Rep (2014) 16:373
TACE regimen. Liver functional reserve is key to an optimal
selection and patients should be in the Child–Pugh A class or
B7 without ascites. A recent expert panel consensus has
recommended a series of absolute and relative contraindica-
tions for the treatment of patients in the intermediate stage [40]
that also apply to the advanced stage.
Tace Using Drug-Eluting Particles
The concept of DEB-TACE is to intra-arterially inject
embolizing particles that have been loaded in vitro with cyto-
toxic agents and slowly release them into the tumor environ-
ment. They are composed of either a sulfonate-modified
poly(vinyl alcohol) hydrogel (DC-Beads, Biocompatibles,
Surrey, UK) or a sodium acrylate and vinyl alcohol copolymer
(HepaSphere, BioSphere Medical, Inc., Rockland, MA,
USA). For the treatment of HCC, these particles can be loaded
with doxorubicin [41]. In a large, international, randomized
trial that compared conventional TACE with DEB-TACE
using DC Beads, the primary endpoints (superiority of DEB-
TACE in achieving objective tumor response at 6 months and
in producing fewer treatment-related serious adverse events in
the first 30 days) were not met [42]. Tumor response rates
were 52 vs. 44 % and time to progression was 7.1 vs.
6.4 months for DEB-TACE and conventional TACE, respec-
tively. Most likely, the expectations in the control arm were
based on early reports on conventional TACE and were thus
overly pessimistic. A similar 6-month response rate of 51 %
was reported for HepaSphere in multicenter study [43].
Furthermore, a prospective, randomized comparison of
DEB-TACE and bland embolization using the same unloaded
particles showed that despite producing a significantly better
response rate at 9 months (55 % vs. 31 %), 12-month survival
was similar (85.3 % vs. 86 %) [44]. Even if it does not
improve survival over conventional TACE, DEB-TACE has
provided a way of performing TACE in a much more stan-
dardized way and has shown that when the optimal patients
are selected, the beneficial effect of TACE can indeed chal-
lenge that of percutaneous ablation. Recent reports on nearly
300 patients in early and intermediate stages from two expe-
rienced centers show 3-year and 5-year survival rates of
62–66 % and 22–38 %, respectively [45]. DEB-TACE is
generally well-tolerated. Major complications occurred in
4.1% of patients in a Greek series [44] including liver abscess,
cholecystitis, pleural effusion, and three cases (1.6 %) of
irreversible liver failure, and in 10 % of patients in a Spanish
series [41], reporting a treatment-related death rate of 0.96 %.
Transarterial Radioembolization
TARE comprises those procedures in which intra-arterially
injected radioactive microspheres are used for internal
radiation treatment [46]. There are two types of commer-
cially available radioactive microspheres made of glass
(TheraSphere; MDS Nordion, Ottawa, Ontario, Canada)
and resin (SIR-Spheres; Sirtex Medical Limited, Sydney,
Australia), although they both use 90Y as the radiation-
emitting isotope. 90Y is a pure beta emitter with half-life of
64.2 hours (94 % of the energy is emitted in the first 11 days)
and average tissue penetration of 2.5 mm (isolation for radi-
ation protection is not needed after implantation). Due to their
small size (25–45 microns), they produce no significant ische-
mic effect as opposed to the greater than 100-micron particles
used in TACE. To avoid misplacement of particles in extra-
hepatic territories, a thorough angiographic evaluation is per-
formed 1–2 weeks prior to treatment to detect and eventually
occlude aberrant vessels arising from hepatic arteries that
may feed the gastrointestinal tract, and to measure the
hepatopulmonary shunting using technetium-99 m-labeled
macroaggregated albumin. Patients can only be considered
for TARE provided their liver function is preserved (serum
total bilirubin <2 mg/dL) and they have no ascites or hepatic
encephalopathy.
No randomized, controlled trial comparing TARE with
others therapies has been published yet, although good level
2 evidence can be compiled from large, well-characterized
cohort series published over the last 5 years [40, 47–51]. By
and large, TARE has been mainly used to treat unresectable
patients considered suboptimal candidates for TACE (those in
advanced stage due to symptoms or PVT or those in interme-
diate stage with very large tumors or extensive bilobar in-
volvement [40]. In these poor TACE candidates, a case-
control study indicated that TARE might improve survival
compared to experimental therapies or best supportive care
(16 vs. 8 months, p<0.05) [52]. When analyzed by tumor
stage, intermediate stage patients treated by TARE reach a
median survival of 16–18 months [49–51] that compares well
with the median survival achieved by TACE. Broadly equiv-
alent survivals have also been reported in retrospective anal-
yses from single institutions although treatment selection and
lead-time biases should be considered. For patients in the
intermediate stage who fail to respond to TACE, remaining
treatment options include the antiangiogenic/antiproliferative
targeted agent sorafenib or TARE. The sorafenib HCC
Assessment Randomized Protocol (SHARP) was the pivotal
phase III, randomized, controlled trial that proved that sys-
temic agent sorafenib prolonged the survival of HCC patients
[53]. The target population was patients not amenable for
TACE, including those with advanced-stage HCC and those
in the intermediate stage that had progressed or were consid-
ered poor TACE candidates. In a subset analysis of the
SHARP trial, survival in patients failing TACE was 11.9 and
9.9 months, respectively, for the sorafenib and placebo-
treatment arms [54]. By comparison, survivalwas 11.4months
for a subset of usual candidates for TARE matching the
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SHARP criteria, and 15.4 months in BCLC B patients failing
TACE [51].
Sorafenib is the mainstay for treating advanced HCC, de-
fined by the presence of vascular invasion, extrahepatic disease
or poor performance status in a patient with at least partially
preserved liver function. As TARE has no macroembolic effect
[55]. it can be safely applied to patients with PVT, and can offer
a median survival in the range of 6–13 months [47, 49–51],
very similar to the 6.5–10.7 months reported in the phase III
clinical trials of sorafenib in the same group of patients [24, 53].
Furthermore, in patients with only branch or segmental PVT,
survival increases to 10–14 months [49, 56, 57]. Due to this
growing body of level 2 evidence, TARE has found a place in
the guidelines adopted by the European Society for Medical
Oncology (ESMO), the European Society of Digestive
Oncology (ESDO), and the National Comprehensive Cancer
Network (NCCN), albeit not in the guidelines of the European
Association for the Study of the Liver (EASL), the European
Organization for Research and Treatment of Cancer (EORTC),
or the American Association for the Study of the Liver
Diseases (AASLD).
The indications described above have been adopted as
standard in many referral centers. Other interesting indications
that are still considered investigational target the population
with less advanced tumors [58]. TARE can induce complete
necrosis in small (< 3 cm) tumors as shown in the analyses of
35 explanted livers [59]. In patients with inoperable early
stage HCC,median time to progression as long as 25.1months
(95 % CI 8–27 months) have been reported [60] and this may
provide a rationale for its use as a bridge to liver transplanta-
tion in an attempt to avoid dropping off the waiting list [61].
The potential to induce intense tumor responses has allowed
TARE to be used as a downstaging therapy, to reduce tumor
burden within acceptable limits for liver transplantation, to
render non-operable patients operable, or to simplify surgery.
Downsizing from UNOS T3 to T2 was achieved more fre-
quently with TARE thanwith TACE (58% vs. 31% p=0.023)
[62]. Furthermore, atrophy of the irradiated lobe after TARE
and contralateral lobe hypertrophy as a result of the injection
of a high activity of 90Y in a lobar hepatic artery, known as
“radiation lobectomy,” may be valuable in itself and contrib-
ute to resectability [63]. In a smaller group of 21 UNOS T3
stage patients, 29 % were downstaged and underwent surgical
resection or liver transplantation, with a 3-year survival rate of
75 % [64], which is comparable with the survival in patients
with early-stage disease who are treated radically at the time of
diagnosis.
TARE is generally well-tolerated and a post-embolization
syndrome like the one that appears after TACE is not com-
mon. Rare complications resulting from the irradiation of non-
tumoral tissues include pneumonitis [65], cholecystitis [66],
gastrointestinal ulcerations [67], and liver damage. Liver tox-
icity is the most challenging adverse event in HCC patients, as
the majority of these tumors arise in cirrhotic livers, with some
degree of reduced functional reserve. A variable incidence of
liver decompensation including ascites (0–18 %) or encepha-
lopathy (0–4 %) has been reported [47, 57, 66, 68–70].
The incidence of radioembolization-induced liver disease
(characterized by jaundice and ascites appearing 4–8 weeks
after TARE) in cirrhotic patients was 9.3 % in the largest series
so far reported [71].
Combinations with Systemic Agents
Tumor hypoxia intentionally caused by TACE can induce
upregulation of circulating vascular endothelial growth factor
(VEGF) [58], which is essential for HCC growth, invasion,
and metastasis. Recent studies have reported a significant
association between VEGF upregulation after TACE and poor
prognosis [72, 73]. Therefore, adjuvant or concurrent use of
an anti-angiogenic agent may be helpful for HCC patients
who are treated with TACE. TACE plus an anti-angiogenic
agent, such as sorafenib, could potentially provide comple-
mentary inhibition of angiogenic factors and tumor growth
[74], and several clinical trials are currently evaluating this
combined effect on the outcome of patients with unresectable
HCC. The results available thus far are somewhat disappoint-
ing. Time to progression among patients with >25 % tumor
necrosis or shrinkage at 1–3 months following one or two
TACE sessions that received sorafenib was not better than that
of patients receiving placebo (5.4 months vs. 3.7 months,
respectively; p=0.25) [75]. When continuous sorafenib or
placebo was given concurrently with DEB-TACE, safety
was not an issue [76] and the hazard ratio for time to
progression was 0.797 in favor of sorafenib (95 % CI
0.588–1.080; p=0.072), but overall survival was comparable
[77]. On the other hand, the addition of TARE to sorafenib for
intermediate- and advanced-stage patients is being explored in
the randomized, controlled SORAMIC trial (NTC 01126645).
The interim analysis of the first 40 patients in the combination
arm has provided further confirmation of its safety [78], and
analysis of survival, which is the primary endpoint, is eagerly
awaited.
External Beam Radiation Therapy
Radiotherapy for HCC is only a recent option made possible
with technological advances in EBRT [79, 80] and commer-
cially available radioactive microsphere products. The liver
architecture consists of a parallel unit structure, which has
specific tolerance parameters regarding ionizing radiation.
Radiation therapy to liver tumors is limited by the relative
radiosensitivity of the sinusoid endothelium, compared to
significantly higher required doses of radiation to confidently
373, Page 4 of 8 Curr Oncol Rep (2014) 16:373
destroy hepatocellular carcinoma cells [81]. Various clinical
and mathematical models have been developed in the past two
decades to understand and predict the risk of organ damage to
radiation total doses, and dose per fraction schedules. These
normal tissue complication probability (NTCP) models are
based on observed complications after radiotherapy in a spe-
cific organ, with known daily and total dose data and specific
clinical outcomes measured [82, 83]. For hepatic radiation
NTCP models, only external beam radiation with photons
(not protons, carbon ions, 90Y, or 131I) has been explored.
The most commonly accepted endpoint in hepatic NTCP
models is radiation-induced liver disease (RILD), classically
reported as TD5/5 and TD50/5. This translates into the total
dose of photon radiation, typically to the whole liver, which
creates a 5 % rate of RILD by 5 years post-radiation, and a
50 % rate respectively [84, 85].
External Beam Radiotherapy for Hepatocellular
Carcinoma (HCC)
Technology advances in radiation oncology in the past 20
years have rapidly expanded radiotherapy accuracy and pre-
cision to all parts of the body. Three-dimensional conformal
radiotherapy (3DCRT) and intensity-modulated radiotherapy
(IMRT) have been mainstays of advanced treatment delivery
using computed tomography (CT)-based datasets to target
tumors while sparing normal surrounding tissues. In the past
decade, a specialized form of 3DCRT, which delivers very
high, single fractions of daily radiation up to five total frac-
tions, has been termed stereotactic body radiotherapy (SBRT).
Challenges in using external beam radiotherapy for HCC are
many, with successes being realized using image-guided ra-
diotherapy (IGRT) to assist in the delivery of 3DCRT, IMRT,
and SBRT, along with respiratory motion compensation and
tumor visualization [81, 86]. The use of proton beam radio-
therapy represents a different type of energy than photons that,
by physical characteristics, can achieve superior dose deposi-
tion compared to 3DCRT [87, 88].
Indications for External Beam Radiotherapy (RT) in HCC
Radiotherapy (RT) can have a meaningful role in all stages of
HCC—with a proven ability to sterilize tumors similarly to
other local ablative approaches like RFA [89]. In the BCLC
classification, Stage 0 and early stage A patients who cannot
undergo surgical resection, transplant, or RFA are candidates
for curative intent radiation therapy. Potentially transplantable
patients can benefit from RTas a bridge to transplant while on
the wait list. In stage B and C, RT has efficacy in situations
where TACE has been ineffective or is unsuitable. This is
particularly important in patients with portal vein invasion
where TACE is contraindicated, and where TARE may not
be possible or ineffective [81, 86].
Stereotactic Body Radiotherapy (SBRT) for HCC
There is strong interest in pursuing SBRT for HCC due to the
increased ability to spare normal liver tissue from receiving
tolerance doses of radiation. Four prospective studies and four
retrospective reports are available from 2006–2011. These
involve a range of 8–60 patients and are limited to single
institutions. Despite the lack of larger, randomized, controlled
data, the positive outcomes in all stages of HCC are proven
with a wide array of fraction sizes and total doses. Excluding
the one study that had only eight patients, the remaining three
used at least five different fractionation schedules adjusted for
Child-Pugh A or B classes. One-year survival ranged from
48–79 % in these heterogeneous groups [90–92].
Proton Beam Therapy (PBT) for HCC
Because of increased control of radiation dose deposition at
any depth in the body, there has been intense interest in using
PBT for HCC [93]. Prospective studies to date using PBT
have been positive regarding toxicity and tumor control, with
encouraging overall survival rates in selected HCC patient
groups in Eastern and Western populations [94–97].
Compared to SBRT, there are more prospective studies (ten),
with each study reporting greater numbers of patients, ranging
from 76 to 318 patients. It is not knownwhether SBRTor PBT
is superior or equivalent in outcomes of HCC patients. Likely,
they will be complementary to each other based on factors
such as tumor size, distribution, and location in the liver.
Dawson has suggested that photon beams (3DCRT, IMRT,
SBRT) might be best employed in Child-Pugh A patients with
tumors in the right lobe near the dome, less than 6 cm in size.
Protons may be utilized best in Child-Pugh B, tumors larger
than 8 cm, and those central/medial in the liver [81, 93]. There
is only level 2a evidence supporting any form of radiation in
HCC, however, combined with the retrospective reports of
hundreds of patients, there is a significant weight of evidence
supporting radiotherapy in all stages of HCC [87, 88].
Conclusions
Hepatocellular carcinoma patients who cannot receive cura-
tive approaches can derive significant benefit in quality of life
and survival if they are eligible for the intraarterial or external
therapies presented. New technologies exploiting both ap-
proaches are being tested clinically, including external radia-
tion using carbon ion beams, combined chemotherapy and
TARE, and variations on TACE, both mechanically and via
the chemotherapy agent deployed.
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It should be recognized that TACE is a heterogeneous
group of procedures in terms of materials, extent and selec-
tivity of vessel occlusion, and timing of repeated sessions.
Good tumor responses are generally observed when a small
number of small tumors are embolized in a selective fashion
(ideally through a distinct feeding vessel). Based on two
positive clinical trials and three meta-analyses, TACE is the
standard of care for HCC patients in the intermediate stage.
DEB-TACE has recently become a more standardized way of
performing TACE with similar outcomes. Y90-RE is a form
of brachytherapy for liver tumors in which the source of
radiation has to access the network of tumor neovascular
plexi. In contrast with TACE, evidence supporting the use of
TARE in the treatment of HCC patients comes from consis-
tent, large-cohort series involving patients with more ad-
vanced HCC, who are not suitable for other locoregional
therapies, or who have failed treatment with TACE.
TACE and TARE should not be considered competing
therapies, but rather complementary tools. For those patients
with small to medium-sized tumors that can be treated selec-
tively, TACE can be provided in most centers. TARE could be
an alternative to repeated TACE for patients that fail to re-
spond to initial TACE, and a first option in those who are poor
candidates to TACE, mainly because of bulky disease and
PVT, but still have a good liver function. The results of
ongoing clinical trials will soon establish whether sorafenib
or other targeted therapies improve the outcome of patients
treated by TACE and TARE.
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